When the healthcare sector sneezes, European investors catch a cold. Healthcare is the single biggest sector in the Stoxx ...

Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...

Spherix has been tracking the C3G market for over four years in both the U.S. and Europe. The studies have provided meaningful insights into physician perceptions of unmet needs and expectations for ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

On the continent, French group Sanofi fell 3.3 per cent and Swiss giants Roche and Novartis shed 2.2 per cent and 1.1 per ...

Qatar is to adopt the Cardio4cities approach – a data-driven cardiovascular population health initiative – and become the ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling ...

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 ...

The project, which includes partners Onyx Equities, Russo Development and Related Fund Management, will introduce new, Class ...

Fitting in a workout after a long day of sitting at a desk might not be enough to compensate for the impacts of sedentary ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...